Medable Inc., the leading technology provider for modern clinical trials, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 15, 2025, at 4:30 pm Pacific Time (7:30 pm Eastern Time).

About Medable

Medable is revolutionizing clinical drug development with its Software as a Service (SaaS) cloud platform. Our Studio plus Medable AI technology is transforming clinical trial evidence data collection, analysis, and application, resulting in increased speed and efficiency to bring life-saving therapies to patients faster. We are accelerating the generation of critical evidence by digitizing and connecting with patients at consumer scale. The flexibility of our technology has powered 300+ clinical trials, across 70+ countries, in 120+ languages, with over 1M patients having utilized our platform, ensuring broader, more diverse patient engagement. Medable is trusted by 14 of the top 20 pharmaceutical companies and all 10 of the top CROs. To date, the company has secured $500M+ in funding from top-tier investors, including Blackstone, Sapphire, PPD/ThermoFisher, and GSR Ventures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217922283/en/